THERAPEUTIC AGENT AND TREATMENT METHOD FOR MULTIPLE SCLEROSIS THROUGH CONCOMITANT ADMINISTRATION OF HUMAN BONE MARROW-DERIVED MESENCHYMAL STEM CELL AND MINOCYCLINE

摘要

The present invention relates to the concomitant administration of a human bone marrow-derived mesenchymal stem cell (hBM-MSC) and minocycline, and alleviates the clinical severity of multiple sclerosis compared to a conventional separate use of minocycline, and solves the problem of exhibiting anti-inflammatory and neuron protective effects and good resistance for long term use but having toxicity to CNS. The concomitant administration of hBM-MSC and minocycline exhibits a remarkable reduction in clinical score compared to the separate use thereof. Further, the concomitant administration of hBM-MSC and minocycline strengthens immunomodulatory effects, suppresses pro-inflammatory cytokines (IFN-γ, TNF-α) and conversely increases anti-inflammatory cytokines (IL-4, IL-10). In addition, the number of apoptotic cells is confirmed to be significantly reduced in TUNEL dyeing if hBM-MSC and minocycline are concomitantly administered compared to the separate use thereof. Therefore, the concomitant administration of hBM-MSC and minocycline can be used for treating multiple sclerosis.